iDFS outcome
The ITT unadjusted analysis for the whole cohort, and among women with ER positive BC, showed that iDFS was slightly improved for patients assigned to 12 years tamoxifen compared to those assigned to 2–3 years (HR = 0.90 (95% CI: 0.81–0.99), The results of the adherence-adjusted analyses are presented in Fig. 